July 25, 2021
3 min watch
Save
VIDEO: Bergo discusses Brimochol trials for presbyopia
Issue: September 10, 2021
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
LAS VEGAS — At the Eyecelerator@ASCRS meeting, Ben Bergo, president and CEO of Visus Therapeutics, discusses Brimochol (carbachol and brimonidine tartrate), the company’s lead candidate for presbyopia.